放射性核素治疗
医学
放射性核素
PARP抑制剂
医学物理学
聚ADP核糖聚合酶
保护
靶向治疗
放射免疫疗法
核医学
癌症治疗
肿瘤科
放射性核素显像
癌症研究
癌症治疗
癌症
精密医学
电流(流体)
选择(遗传算法)
临床试验
药理学
内科学
剂量学
生物信息学
作者
Ahmad Kurniawan,Luis Hernández Cano,Nerea Delgado Mayenco,Sreelakshmi Unnikrishnan,Philip H. Elsinga,Ines Farinha Antunes,Erik F. J. de Vries,Bart T. Cornelissen
标识
DOI:10.1007/s00259-026-08016-9
摘要
In recent years, numerous studies have investigated the use of poly (ADP-ribose) polymerase (PARP) inhibitors, labelled with various radionuclides, as agents for targeted radionuclide therapy. This review discusses current advances in studies with radiolabelled PARP inhibitors for targeted radionuclide therapy, focusing on radionuclide selection and (radio)biological properties. We highlight differences between radionuclides and their efficacy in killing cancer cells, while safeguarding healthy tissue. Furthermore, important biomarkers and dosimetry are explored, providing insights and future directions for advancing radiolabelled PARP inhibitors.
科研通智能强力驱动
Strongly Powered by AbleSci AI